small interfering RNA + gemcitabine

This term most plausibly refers to an **investigational combination regimen** pairing a therapeutic small interfering RNA with **gemcitabine** chemotherapy, rather than a single uniquely defined drug product. In the published clinical literature, the best documented example is **Atu027 + gemcitabine** for advanced pancreatic carcinoma, where Atu027 is a liposomal siRNA designed to silence **protein kinase N3** in vascular endothelium, with the goal of reducing tumor progression and metastasis, while gemcitabine acts as a deoxycytidine analogue that inhibits DNA synthesis in proliferating tumor cells. Because the query does not specify which siRNA agent is meant, the exact active siRNA payload, developer, formulation, and disease setting cannot be assigned uniquely; the phrase therefore describes a nonspecific siRNA chemotherapy combination concept rather than a single canonical commercial product.

Other names

siRNA + gemcitabinesmall interfering RNA + gemcitabine